AI-generated summary
The authors report a clinical trial of 62 infants with infantile hemangiomas treated with intense pulsed light using optimal pulse technology, typically four to five sessions. They report improvement in 76% of lesions, with transient adverse events in under 5% of treatments and no scarring or pigmentary changes. The authors conclude the approach is safe and effective.
- Participants
- 62
- Who or what was studied
- Infants with infantile hemangioma, mean age 6 months, Fitzpatrick skin types III or IV
- Limits stated in the abstract
- The abstract describes a single clinical trial without a control group and reports improvement based on comparison of photographs and parental satisfaction scores.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Adverse event. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.